Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
JAMA Intern Med
.
2015 Dec;175(12):1992-4.
doi: 10.1001/jamainternmed.2015.5868.
Authors
Chul Kim
1
,
Vinay Prasad
2
Affiliations
1
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
2
Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland.
PMID:
26502403
DOI:
10.1001/jamainternmed.2015.5868
No abstract available
MeSH terms
Antineoplastic Agents / therapeutic use*
Drug Approval / methods*
Endpoint Determination
Follow-Up Studies
Humans
United States
United States Food and Drug Administration
Substances
Antineoplastic Agents